1 / 14

Enhancing Compliance through the medAmigo Intervention Program in Biopharmaceutical Sciences

The medAmigo Intervention Program offers a revolutionary approach to improve patient compliance in biopharmaceutical contexts. It revolves around the concept that empowering patients helps their doctors provide better care, emphasizing the importance of realistic measurement and continuous electronic tracking of medication adherence. With included physician and patient feedback and scheduled appointments for ongoing review, the program has demonstrated significant success across various conditions, including hypertension and osteoporosis. This model is pivotal for enhancing medication management and improving health outcomes.

lael
Télécharger la présentation

Enhancing Compliance through the medAmigo Intervention Program in Biopharmaceutical Sciences

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE MISSING LINK IN BIOPHARMACEUTICAL SCIENCESTM The Intervention Program

  2. A basic principle “Help your doctor help you”

  3. medAmigo intervention program medAmigo med=medicine, Amigo=Friend

  4. Screening vs. Algorithms & Interventions Plans Monitoring & Data Collection Intervention Plan Selected Physician & Patient Feedback Physician & Patient Feedback Intervention medAmigo patient management model Patient Starts

  5. Measurement-Guided Medication Management (MGMM) based intervention Successful techniques for improving compliance require two key elements: • Realistic measurement • the objective, continuous electronic recording of day by day dosing times, which can be easily interpreted by most patients • Scheduled appointments with feedback • continuing periodic review with the patient, by the prescribing physician, pharmacist, or nurse of the patient’s ongoing dosing history.

  6. Days on treatment Illustrative results of a medAmigo intervention Treatment of osteoporosis Before intervention After intervention Dosing Time V= a missed dose, 0= Sunday; 1= Monday; 2= Tuesday; 3= Wednesday;…

  7. MGMM tested successfully in Hypertension 12 weeks data No Intervention (N = 34) Mean compliance = 78% Intervention (N = 36) Mean compliance = 95% Difference = 17% McKenney et al., 1992 J Clin Pharmacol

  8. MGMM tested successfully in Hypertension McKenney et al., 1992 J Clin Pharmacol

  9. MGMM tested successfully in Serious Mental Illness Cramer and Rosenheck, 1999 J of Nervous & Mental Diseases

  10. MGMM tested successfully in Resistant Hypertension Burnier et al., 2001 J of Hypertension

  11. Dose compliance ** * * ** Week MGMM tested successfully in Smoking Cessation InterventionN = 51 Difference of ± 30% No Intervention N = 46 * p<0.05 ** p<0.001 Schmitz et al., 2005, Journal of Behavioral Medicine

  12. MGMM tested successfully in HIV • N=26 experienced patients (>6 months on treatment) 2 months 3 months Intervention 82% 93% Difference = 11%, p<0.05 Larger confirmatory trial is ongoing De Bruin et al., 2005 Aids Patient Care

  13. Intervention No Intervention MGMM tested successfully in Lipid Lowering Daily Percentage of adherers 100 90 ~86% % 80 Difference of 15% ~71% 70 P<0.01 60 0 50 100 150 200 250 300 Days since inclusion Vrijens, et al., Pharmacoepidemiology and Drug Safety, 2006

  14. Industry WINS Timely detection, focused Intervention Patients LOSE Late dropouts; retained sales Payors WIN Decreased care costs Payors LOSE Patients WIN Industry LOSES Increased drug efficacy Robust adherence/long persistence Breaking the downward spiral Poor adherence/short persistence Decreased drug efficacy Increased care costs Early dropouts; lost sales

More Related